Skip to main content

Advertisement

SpringerLink
Log in

Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer. Methods Forty patients with ≤5 metastatic lesions received curative-intent SBRT, while 11 patients with >5 lesions, undergoing SBRT to ≤5 metastatic lesions, were treated with palliative-intent. Results Among those treated with curative-intent, 4-year actuarial outcomes were: overall survival of 59%, progression-free survival of 38% and lesion local control of 89%. On univariate analyses, 1 metastatic lesion (versus 2–5), smaller tumor volume, bone-only disease, and stable or regressing lesions prior to SBRT were associated with more favorable outcome. Patients treated with palliative-intent SBRT were spared morbidity and mortality from progression of treated lesions, though all developed further metastatic progression shortly (median 4 months) after enrollment. Conclusions SBRT may yield prolonged survival and perhaps cure in select patients with limited metastases. Palliative-intent SBRT may be warranted for symptomatic or potentially symptomatic metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rubin P, Green J (1968) Solitary metastases. Charles C. Thomas, Springfield, IL

    Google Scholar 

  2. Milas L, Hunter N, Withers HR (1976) Concomitant immunity to pulmonary metastases of a murine fibrosarcoma: influence of removal of primary tumor by radiation or surgery, of active specific immunization and treatment with Corynebacterium granulosum. Int J Radiat Oncol Biol Phys 1:1171–1178

    PubMed  CAS  Google Scholar 

  3. Rosenberg SA (1987) Surgical treatment of metastatic cancer. Lippincott Williams & Wilkins, Philadelphia, PA

    Google Scholar 

  4. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10

    PubMed  CAS  Google Scholar 

  5. Hellman S (1994) Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol 12:2229–2234

    PubMed  CAS  Google Scholar 

  6. Fisher B (1980) Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 40:3863–3874

    PubMed  CAS  Google Scholar 

  7. Fisher B, Redmond C, Fisher ER (1980) The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology—an overview of findings. Cancer 46:1009–1025. doi :10.1002/1097-0142(19800815)46:4<1009::AID-CNCR2820461326>3.0.CO;2-H

    Article  PubMed  CAS  Google Scholar 

  8. Mehta N, Mauer AM, Hellman S et al (2004) Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 25:1677–1683

    PubMed  Google Scholar 

  9. Singletary SE, Walsh G, Vauthey JN et al (2003) A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8:241–251. doi:10.1634/theoncologist.8-3-241

    Article  PubMed  Google Scholar 

  10. Tait CR, Waterworth A, Loncaster J et al (2005) The oligometastatic state in breast cancer: hypothesis or reality. Breast 14:87–93. doi:10.1016/j.breast.2004.10.003

    Article  PubMed  Google Scholar 

  11. Carey Sampson M, Katz A, Constine LS (2006) Stereotactic body radiation therapy for extracranial oligometastases: does the sword have a double edge? Semin Radiat Oncol 16:67–76. doi:10.1016/j.semradonc.2005.12.002

    Article  PubMed  Google Scholar 

  12. Timmerman RD, Kavanagh BD, Cho LC et al (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947–952. doi:10.1200/JCO.2006.09.7469

    Article  PubMed  Google Scholar 

  13. Kavanagh BD, McGarry RC, Timmerman RD (2006) Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 16:77–84. doi:10.1016/j.semradonc.2005.12.003

    Article  PubMed  Google Scholar 

  14. Katz AW, Carey-Sampson M, Muhs AG et al (2006) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 67:793–798. doi:10.1016/j.ijrobp.2006.10.025

    PubMed  Google Scholar 

  15. Okunieff P, Petersen AL, Philip A et al (2006) Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol 45:808–817. doi:10.1080/02841860600908954

    Article  PubMed  Google Scholar 

  16. Milano MT, Katz AW, Schell MC et al (2008) Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (in press)

  17. Milano MT, Katz AW, Muhs AG et al (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112:650–658. doi:10.1002/cncr.23209

    Article  PubMed  Google Scholar 

  18. Singh D, Yi WS, Brasacchio RA et al (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58:3–10. doi:10.1016/S0360-3016(03)01442-1

    Article  PubMed  Google Scholar 

  19. O’Dell WG, Schell MC, Reynolds D et al (2002) Dose broadening due to target position variability during fractionated breath-held radiation therapy. Med Phys 29:1430–1437. doi:10.1118/1.1485977

    Article  PubMed  Google Scholar 

  20. Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205

    Article  PubMed  CAS  Google Scholar 

  21. Rivera E, Holmes FA, Buzdar AU et al (2002) Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 8:2–9. doi:10.1046/j.1524-4741.2002.08002.x

    Article  PubMed  CAS  Google Scholar 

  22. Buzdar AU, Blumenschein GR, Montague ED et al (1984) Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol 7:45–50. doi:10.1097/00000421-198402000-00006

    Article  PubMed  CAS  Google Scholar 

  23. Holmes FA, Buzdar AU, Kau S-W (1994) Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED): the M.D. Anderson experience. Breast Dis 7:7–20

    Google Scholar 

  24. Blumenschein GR, DiStefano A, Caderao J et al (1997) Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res 3:2633–2637

    PubMed  CAS  Google Scholar 

  25. Nieto Y, Cagnoni PJ, Shpall EJ et al (1999) Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 5:1731–1737

    PubMed  CAS  Google Scholar 

  26. Nieto Y, Nawaz S, Jones RB et al (2002) Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20:707–718. doi:10.1200/JCO.20.3.707

    Article  PubMed  CAS  Google Scholar 

  27. Hanrahan EO, Broglio KR, Buzdar AU (2005) Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 104:1158–1171. doi:10.1002/cncr.21305

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the family of Barbara Fogarty for their support. We also thank Laura Brumbaugh for editorial assistance. Paul Okunieff, M.D., received grant support from BrainLAB AG (Heimstetten, Germany) between April 1, 2000, and March 31, 2005.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave, P.O. Box 647, Rochester, NY, 14642, USA

    Michael T. Milano, Hong Zhang, Su K. Metcalfe, Ann G. Muhs & Paul Okunieff

Authors
  1. Michael T. Milano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Su K. Metcalfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ann G. Muhs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul Okunieff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael T. Milano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milano, M.T., Zhang, H., Metcalfe, S.K. et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 115, 601–608 (2009). https://doi.org/10.1007/s10549-008-0157-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0157-4

Keywords

Search

Navigation